Robert Harte
About
In The Last Decade
Robert Harte
12 papers receiving 306 citations
Peers
Comparison fields: 5 of 49
- Radiology, Nuclear Medicine and Imaging 142
- Oncology 111
- Surgery 99
- Pulmonary and Respiratory Medicine 86
- Molecular Biology 35
Countries citing papers authored by Robert Harte
This map shows the geographic impact of Robert Harte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Harte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Harte more than expected).
Fields of papers citing papers by Robert Harte
This network shows the impact of papers produced by Robert Harte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Harte. The network helps show where Robert Harte may publish in the future.
Co-authorship network of co-authors of Robert Harte
This figure shows the co-authorship network connecting the top 25 collaborators of Robert Harte. A scholar is included among the top collaborators of Robert Harte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Harte. Robert Harte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 15 | |
| 2 | 94 | |
| 3 | 2 | |
| 4 | 57 | |
| 5 | 44 | |
| 6 | Sources of error in tissue and tumor measurements of 5-[18F]fluorouracil. | 11 |
| 7 | 42 | |
| 8 | 6 | |
| 9 | Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials. | 15 |
| 10 | 2 | |
| 11 | 9 | |
| 12 | New techniques in the pharmacokinetic analysis of cancer drugs. IV. Positron emission tomography. | 14 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.